Click me
Transcript

Drug Stats

Annualized Relapse Rate 1.5 MS Drug Stats 2013 1.31 1.28 1.0 0.90 0.87 0.84 0.82 0.5 0.60 0.67 0.74 0.41 0.41 0.49 0.54 0.40 0.52 0.0 0.24 0.37 0.25 0.15 0.40 0.18 0.22 0.26 0.39 0.26 0.30 Betaseron 0.17 0.22 0.18 Anovex Lemtrada CARE-MS I sc Interferon Beta-1a Gilenya 0.09 Aubagio Rates of Disabilties BG-12 Treatment effect placebo 40.0% Treatment effect 37.0 35.0% Hazard Ratio: Statistically Significant: p = 0.01 34.9 0.85 30.0% 25.0% 0.80 p = 0.02 29.0 26.0 25.0 0.96 NS 20.0% 27.3 0.58 p< 0.001 22.0 24.0 21.9 0.70 p< 0.03 15.0% 0.70 p < 0.001 10.0% 17.0 20.2 18.0 11.0 13.0 17.0 5.0% 0.66 p< 0.001 16.0 12.0 11.0 0.64 p< 0.01 0.66 13.0 0.0% NS 3.0 6.0 8.0 11.0 7.1 Rebif etaseron 3.0 Anovex 4.0 5.0 Tysabri Gilenya Treatment effects Aubagio Percentage of Patients Disease Free After 2 Years Treatment effects BG-12 Treatment effects Laquinimod Treatment effects 56.0% 25.0% 32.0% 38.0% 16.0% 15.0% 26.0% 26.0% 56.6% 41.0% 67.0% placebo Betaseron 45.6% 46.0% placebo Rebif placebo 70.0% 56.0% placebo Anovex 59.0% Сарохоnе pivotal 62.9% placebo Tysabri 74.0% 52.2% placebo Gilenya 71.0% placebo Aubagio sc Interferon Beta-1a Lemtrada CARE-MS I Placebo Rate placebo BG-12 placebo Laquinimod 2011 Sales Betaseron 1.31 O Rebif 1.28 Сорахоne $3,925,000,000 Gilenya $494,000,000 Betaseron $1,495,000,000 Copaxone 0.84 Tysabri $1,511,000,000 Total $12,413,000,000 oLaquinimod 0.39 Avonex $2,738,000,000 Rebif $2,250,000,000 Betaseron Rebif Route of Delivery Сарохопе Avonex Subcutaneous injection Subcutaneous injection Tysabri Gilenya Subcutaneous injection Subcutaneous injection Aubagio Lemtrada Frequency of Administration IV infusion BG-12 Oral Every other day Laquinimod Oral Every other day Once a day IV infusion Once a week Oral Once a month Oral Cycle consisting 2 infusions, one month apart, repeated 12 Top Safety Complaints Once a day Once a day Flu-like symptoms Flu-like symptoms Injection site reactions Twice a day • Headache Once s day Flu-like symptoms • Bradycardia months later Fatigue • Diarrhea • Conduction Block • New onset • Infections • Hair loss Black Box Warning and Special Considerations • Liver enzyme elevation autoimmune disease • Headache • Liver enzyme elevation Flushing None • Infection Yes, progressive multifocal leukoencephalopathy thought to be caused by JC virus; screening for JC antibody status • UTI None None • Liver enzyme elevation None No, but first dose No, but pregnancy category X 2011 Sales observation is required Not yet approved $1,495,000,000 recommended Not yet approved $2,250,000,000 $3,925,000,000 Not yet approved $2,738,000,000 $1,511,000,000 $494,000,000 placebo Treatment effect Rebif placebo Treatment effect Capoxone pivotal placebo Treatment effect N/A placebo N/A placebo Treatment effect placebo Treatment effects Tysabri placebo Capoxone pivotal placebo placebo Treatment effect placebo placebo Treatment effect 93 - a Avonex 0.82 placebo Treatment effects 93 - 95 - O Tysabri 0.74 Treatment effect placebo Treatment effects 96 1- Gilenya 0.40 05 - placebo a Aubagio 0.54 09 placebo oLemtrada 0.52 Laquinimod |1 - Treatment effect Lemtrada CARE-MS I sc Interferon Beta-1a o BG-12 0.40 12 Treatment effects |2 1 12| placebo placebo Treatment effects Annualized Relapse Rate 1.5 MS Drug Stats 2013 1.31 1.28 1.0 0.90 0.87 0.84 0.82 0.5 0.60 0.67 0.74 0.41 0.41 0.49 0.54 0.40 0.52 0.0 0.24 0.37 0.25 0.15 0.40 0.18 0.22 0.26 0.39 0.26 0.30 Betaseron 0.17 0.22 0.18 Anovex Lemtrada CARE-MS I sc Interferon Beta-1a Gilenya 0.09 Aubagio Rates of Disabilties BG-12 Treatment effect placebo 40.0% Treatment effect 37.0 35.0% Hazard Ratio: Statistically Significant: p = 0.01 34.9 0.85 30.0% 25.0% 0.80 p = 0.02 29.0 26.0 25.0 0.96 NS 20.0% 27.3 0.58 p< 0.001 22.0 24.0 21.9 0.70 p< 0.03 15.0% 0.70 p < 0.001 10.0% 17.0 20.2 18.0 11.0 13.0 17.0 5.0% 0.66 p< 0.001 16.0 12.0 11.0 0.64 p< 0.01 0.66 13.0 0.0% NS 3.0 6.0 8.0 11.0 7.1 Rebif etaseron 3.0 Anovex 4.0 5.0 Tysabri Gilenya Treatment effects Aubagio Percentage of Patients Disease Free After 2 Years Treatment effects BG-12 Treatment effects Laquinimod Treatment effects 56.0% 25.0% 32.0% 38.0% 16.0% 15.0% 26.0% 26.0% 56.6% 41.0% 67.0% placebo Betaseron 45.6% 46.0% placebo Rebif placebo 70.0% 56.0% placebo Anovex 59.0% Сарохоnе pivotal 62.9% placebo Tysabri 74.0% 52.2% placebo Gilenya 71.0% placebo Aubagio sc Interferon Beta-1a Lemtrada CARE-MS I Placebo Rate placebo BG-12 placebo Laquinimod 2011 Sales Betaseron 1.31 O Rebif 1.28 Сорахоne $3,925,000,000 Gilenya $494,000,000 Betaseron $1,495,000,000 Copaxone 0.84 Tysabri $1,511,000,000 Total $12,413,000,000 oLaquinimod 0.39 Avonex $2,738,000,000 Rebif $2,250,000,000 Betaseron Rebif Route of Delivery Сарохопе Avonex Subcutaneous injection Subcutaneous injection Tysabri Gilenya Subcutaneous injection Subcutaneous injection Aubagio Lemtrada Frequency of Administration IV infusion BG-12 Oral Every other day Laquinimod Oral Every other day Once a day IV infusion Once a week Oral Once a month Oral Cycle consisting 2 infusions, one month apart, repeated 12 Top Safety Complaints Once a day Once a day Flu-like symptoms Flu-like symptoms Injection site reactions Twice a day • Headache Once s day Flu-like symptoms • Bradycardia months later Fatigue • Diarrhea • Conduction Block • New onset • Infections • Hair loss Black Box Warning and Special Considerations • Liver enzyme elevation autoimmune disease • Headache • Liver enzyme elevation Flushing None • Infection Yes, progressive multifocal leukoencephalopathy thought to be caused by JC virus; screening for JC antibody status • UTI None None • Liver enzyme elevation None No, but first dose No, but pregnancy category X 2011 Sales observation is required Not yet approved $1,495,000,000 recommended Not yet approved $2,250,000,000 $3,925,000,000 Not yet approved $2,738,000,000 $1,511,000,000 $494,000,000 placebo Treatment effect Rebif placebo Treatment effect Capoxone pivotal placebo Treatment effect N/A placebo N/A placebo Treatment effect placebo Treatment effects Tysabri placebo Capoxone pivotal placebo placebo Treatment effect placebo placebo Treatment effect 93 - a Avonex 0.82 placebo Treatment effects 93 - 95 - O Tysabri 0.74 Treatment effect placebo Treatment effects 96 1- Gilenya 0.40 05 - placebo a Aubagio 0.54 09 placebo oLemtrada 0.52 Laquinimod |1 - Treatment effect Lemtrada CARE-MS I sc Interferon Beta-1a o BG-12 0.40 12 Treatment effects |2 1 12| placebo placebo Treatment effects

Drug Stats

shared by eclutter on Apr 27
239 views
1 shares
0 comments
Visual breakdown of 9 leading MS drugs on the market. A range of data that was placed on a larger map for further information about the companies and drugs.

Source

Unknown. Add a source

Category

Health
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size